

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Adams, Julian, et al.		
Application No.:	10/730,231	Group No.:	1626
Filed:	December 8, 2003	Examiner:	Coppins, Janet L.
For:	BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

## List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. [x] Preliminary Statements
2. [x] Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449)
3. [x] Copy of Listed Information Items Accompanying This Statement (Citation Nos. BBC, CCB-CCF)

## CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

## MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## 37 C.F.R. SECTION 1.8(a)

- ☒ with sufficient postage as first class mail.

## 37 C.F.R. SECTION 1.10\*


- ☐ as "Express Mail Post Office to Addressee"  
Mailing Label No.

## TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: April 11, 2005

  
Beverly Sotiropoulos  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

**Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Copies of Listed Information Items Accompanying This Statement**

Legible copy of items (BBC, CCB-CCF) listed in Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement.

April 11, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By: Janice M. Klunder  
Janice M. Klunder, Ph.D.  
Registration No. 41,121  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-551-3699  
Facsimile - 617-551-8820  
Facsimile - 617-551-8820

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

## Complete if Known

Application Number	10/730,231
Filing Date	December 8, 2003
First Named Inventor	Adams, Julian, et al.
Group Art Unit	1626
Examiner Name	Coppins, Janet L.
Attorney Docket Number	MPI94-008CP2DV2CN5M

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Code <sup>5</sup> Office <sup>3</sup>	Number <sup>4</sup> (if known)	Kind				
	BBC	WO	94/04653	A1	The Procter & Gamble Company (US)	03-03-1994	Entire Document	

Examiner

Date

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, P.O. Box 1450, Alexandria, VA 22313-1450.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(use as many sheets as necessary)</p>				<h3 style="text-align: center; margin: 0;">Complete if Known</h3> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Application Number</td> <td>10/730,231</td> </tr> <tr> <td>Filing Date</td> <td>December 8, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Adams, Julian, et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>1626</td> </tr> <tr> <td>Examiner Name</td> <td>Coppins, Janet L.</td> </tr> <tr> <td>Attorney Docket Number</td> <td>MPI94-008CP2DV2CN5M</td> </tr> </table>		Application Number	10/730,231	Filing Date	December 8, 2003	First Named Inventor	Adams, Julian, et al.	Group Art Unit	1626	Examiner Name	Coppins, Janet L.	Attorney Docket Number	MPI94-008CP2DV2CN5M
Application Number	10/730,231																
Filing Date	December 8, 2003																
First Named Inventor	Adams, Julian, et al.																
Group Art Unit	1626																
Examiner Name	Coppins, Janet L.																
Attorney Docket Number	MPI94-008CP2DV2CN5M																
Sheet	1	of	1														

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	CCB	Elgendy, Said, et al., "New Peptide Boronic Acid Inhibitors of Thrombin", <i>Tetrahedron Letters</i> , Vol. 33, No. 29, pp. 4209-4212, (1992).	
	CCC	Amiri, Payman, et al., "Benzamidomethaneboronic Acid: Synthesis and Inhibition of Chymotrypsin," <i>Archives of Biochemistry and Biophysics</i> , Vol. 234, No. 2, pp. 531-536, (November 1, 1984).	
	CCD	Philipp, Manfred, et al., "Inhibition of Subtilisin By Substituted Arylboronic Acids" <i>FEBS Letters</i> , Vol. 133, No. 1, pp. 36-38, (October 1981).	
	CCE	"Aminomethaneboronic Acids. Synthesis and Inhibition of a Boron Analogue of Esterase Substrates", <i>Journal of the American Chemical Society</i> , Vol. 99, No. 19, pp. 6435-6437 (September 14, 1977).	
	CCF	Orlowski, Marian, et al., "Pituitary Multicatalytic Proteinase Complex. Specificity of Components and Aspects of Proteolytic Activity" <i>Biochemistry</i> , Vol. 28, No. 24, pp. 9270-9278, (1989).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.